AKELA Pharma Inc. enrolls first patient in its Phase IIb CGRP trial

29-Aug-2007

AKELA Pharma Inc., a drug development company focused on developing therapies for the inhalation, pain and CNS markets, announced that it has enrolled the first patient in the CGRP Phase IIb clinical trial.

CGRP Phase IIb is a multi-centered, double-blind, placebo controlled, randomized cross-over study to evaluate the effects of inhaled CGRP on clinical and inflammatory parameters in adult patients with mild asthma following allergen challenge test. A total of 16 patients will be enrolled in two randomized one week treatment periods (either 5mg CGRP b.i.d. or placebo).

Akela CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances